Drug Trial Radar · NCT05136170
Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease
Last checked: Nov 20, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
Jan 27, 2022
Primary completion
May 24, 2023
Study completion May 24, 2023
Sponsor
- Lead sponsor
- Dompé Farmaceutici S.p.AIndustry
- Sponsor type
- Industry
- First posted
- Nov 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objectives: * To compare the efficacy of cenegermin vs vehicle in Schirmer I test (without anaesthesia) \> 10 mm/5 min at Week 4 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in Symptom Assessment in Dry Eye questionnaire (SANDE) global score at Week 12 by testing the superiority. Secondary Objectives: * To compare the efficacy of cenegermin vs vehicle in Schirmer I test at Week 4, 8, 12 and 16 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in Cornea and conjunctiva vital staining with fluorescein (National Eye Institute \[NEI\] scales) at Week 4, 8, 12 and 16 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in Tear Film Break-Up Time (TFBUT) at Week 4, 8, 12 and 16 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in SANDE scores at Week 8, 12 and 16 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in worsening in symptom scores (SANDE) and/or NEI score at Week 4 by testing the superiority. * To compare the efficacy of cenegermin vs vehicle in impact of dry eye on everyday life (IDEEL) questionnaire at Week 4, 8, 12 and 16 by testing the superiority.
Conditions
- Dry Eye Disease
Interventions
CenegerminDrug
Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID) for 28 consecutive days.
VehicleOther
Vehicle was instilled with the same scheme of the test product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With Schirmer I Test (Without Anesthesia) >10mm/5min in the Eligible Eye at Week 4Time frame: At Week 4 (Visit 3)
- Change From Baseline in Symptom Questionnaire (SANDE) Global Score at Week 12Time frame: At Week 12 (Visit 5 - Follow up)
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Lugene Eye Institute - Glendale Office
Glendale, California
The Johns Hopkins University
Baltimore, Maryland
Tufts University School of Medicine (TUSM) - New England Eye Center/Tufts Medical Center
Boston, Massachusetts
OCLI (Ophthalmic Consultants of Long Island)
Garden City, New York
Scheie Eye Institute
Philadelphia, Pennsylvania
Houston Eye Associates HEA - Gramercy Location
Houston, Tennessee
Toyos Clinic - Nashville
Nashville, Tennessee
AOU Gaspare Rodolico - Ospedale San Marco
Catania, Italy
Università degli Studi di Milano - Ospedale San Giuseppe - UO Oculistica
Milan, Italy
AOU Policlinico Umberto I - Dipartimento Organi di Senso - Clinica Oculistica
Roma, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.